Finasteride

Generic Name
Finasteride
Brand Names
Entadfi, Propecia, Proscar
Drug Type
Small Molecule
Chemical Formula
C23H36N2O2
CAS Number
98319-26-7
Unique Ingredient Identifier
57GNO57U7G
Background

Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an ...

Indication

Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. A combination product with tadalafil is also used...

Associated Conditions
Androgenetic Alopecia (AGA), Benign Prostatic Hyperplasia (BPH), Idiopathic Hirsutism, Symptomatic benign prostatic hyperplasia (BPH)
Associated Therapies
-
Clinical Trials
Related News

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

First Posted Date
2010-06-09
Last Posted Date
2013-02-27
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
696
Registration Number
NCT01139762
Locations
🇹🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey

Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Finasteride
First Posted Date
2010-05-28
Last Posted Date
2010-07-12
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
24
Registration Number
NCT01133444
Locations
🇨🇦

MDS Pharma Services, Cohen street, saint-laurent, montreal (quebec), Canada

Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Finasteride
First Posted Date
2010-05-28
Last Posted Date
2010-05-28
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
24
Registration Number
NCT01133457
Locations
🇨🇦

MDS Pharma Services, Cohen street, saint-laurent, montreal (quebec), Canada

Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia

Phase 1
Completed
Conditions
Androgenetic Alopecia
Interventions
Drug: Finasteride
First Posted Date
2010-01-20
Last Posted Date
2010-01-20
Lead Sponsor
HairDx, LLC
Target Recruit Count
12
Registration Number
NCT01052870

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

Phase 1
Completed
Conditions
Retinal Disease
Interventions
Drug: Finasteride
First Posted Date
2009-02-05
Last Posted Date
2016-09-26
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
5
Registration Number
NCT00837252
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

First Posted Date
2008-09-25
Last Posted Date
2012-06-14
Lead Sponsor
Nymox Corporation
Target Recruit Count
85
Registration Number
NCT00759135
Locations
🇺🇸

Nymox Investigational Site, San Antonio, Texas, United States

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

First Posted Date
2008-08-18
Last Posted Date
2023-10-02
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
55
Registration Number
NCT00736645
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

ORAL T-6: Oral Androgens in Man-6

First Posted Date
2008-04-22
Last Posted Date
2011-01-24
Lead Sponsor
University of Washington
Target Recruit Count
16
Registration Number
NCT00663793
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

Phase 2
Terminated
Conditions
Hematuria
Hematospermia
Interventions
Drug: Finasteride
First Posted Date
2008-01-25
Last Posted Date
2014-01-31
Lead Sponsor
University of British Columbia
Target Recruit Count
29
Registration Number
NCT00600691
Locations
🇨🇦

Royal Jubilee Hospital, Victoria, British Columbia, Canada

🇨🇦

Victoria General Hospital, Victoria, British Columbia, Canada

On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)

Phase 3
Withdrawn
Conditions
Benign Prostatic Hyperplasia
Interventions
Drug: Placebo
Drug: Finasteride
First Posted Date
2007-11-28
Last Posted Date
2017-10-30
Lead Sponsor
University of Alberta
Registration Number
NCT00564460
Locations
🇨🇦

Alberta Urology Institute, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy